Similarly, considering Parkinson’s disease pathology, Toll-like receptor 2/4 in the gut is targeted to mitigate α-synuclein aggregation and pathological changes by modifying the gut–brain axis diffusion pattern through lifestyle interventions, probiotics, or specific therapies. Here, TLR2 is linked to Parkinson disease.